Response Genetics Inc. (RGDXQ)

Overview

Response Genetics, Inc. is a life sciences company deeply engaged in the oncology realm, focusing on researching, developing, marketing, and selling pharmacogenomic tests that are instrumental in cancer treatment across the United States, Europe, and other international locations. The tests it offers are critical for measuring predictive factors for therapy responses in tumor tissue samples, enabling personalized treatment approaches for cancer patients. Initially known as Bio Type, Inc., the company underwent a rebranding to Response Genetics, Inc. in August 2000. Since its inception in 1999, Response Genetics has established its headquarters in Los Angeles, California, positioning itself as a pivotal player in the cancer diagnostics and treatment optimization industry.

Products and Services

Response Genetics, Inc. provides a wide range of testing services tailored to various cancer types, through its comprehensive test suites. Each product focuses on delivering predictive analysis for therapy response in specific cancers:

• ResponseDX: Lung - Offers testing services for non-small cell lung cancer, helping to identify the most effective treatment approaches based on the genetic makeup of the tumor.
• ResponseDX: Colon - Specializes in colorectal cancer, providing vital information about genetic factors that influence treatment success.
• ResponseDX: Gastric - Focuses on gastric and gastroesophageal cancer, offering insights into potential therapy responses, aiding in the selection of targeted treatment plans.
• ResponseDX: Melanoma - Designed for melanoma, this service helps in determining the most promising therapeutic strategies through genetic analysis.
• ResponseDX: Thyroid - Supports thyroid cancer treatment decision-making with test results that estimate response to various therapies.
• ResponseDX: Breast - Provides testing services for breast cancer, aiming to match patients with the most effective personalized treatment options.
• ResponseDX: Glioma - Offers genetic testing services for glioma, a type of brain tumor, to predict treatment outcomes and optimize therapy plans.
• ResponseDX: Tissue of Origin - A unique test suite that identifies the original tissue type of the cancer, aiding in determining the most appropriate treatment pathway.

In addition to these targeted testing services, Response Genetics, Inc. is also actively developing tests for other tumor types to expand its diagnostic repertoire. The company provides both technical component and professional component testing services, ensuring comprehensive support for its clients, which include community-based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies. By leveraging a dedicated sales force, Response Genetics, Inc. ensures its innovative testing solutions are accessible to a wide range of healthcare providers, aiming to significantly impact the cancer treatment landscape by offering precise, personalized diagnostic and treatment solutions.